Malvern Institute

Stay Connected With Malvern. Get Email Updates

info@malverninstitute.com | Follow Us:

Local woman testifies about Big Pharma’s role in daughter’s overdose death

September 13, 2017 – Local communities and families are standing up against pharmaceutical companies for misleading patients about the dangerous effects of opioids.

According to philly.com, the U.S. Senate held a hearing about the marketing practices of the pharmaceutical industry.

Deborah Fuller, of Cherry Hill, shared her thoughts that Insys Therapeutics Inc. contributed to the overdose death of her daughter, 32-year-old Sarah Fuller.

Malvern Institute operates an outpatient center in Cherry Hill, located at 401 Kings Highway, Building #1.

Her mother, Deborah, described listening to an audio recording in which a drug company representative falsely said she was from Sarah’s doctor’s office and misled a pharmacy benefits manager into believing that Sarah had breakthrough cancer pain. That’s the only condition that Insys’ fast-acting fentanyl brand, Subsys, was approved to treat.

“Every day of my life, I must live with the realization that Sarah is gone because of Insys’ greed,” Fuller said. “I believe that Sarah’s death certificate should be changed to indicate her death was a homicide and the cause of death should be changed to ‘corporate greed.’”

If you or a loved one are living with addiction and have any questions about the Malvern Intervention Services or the Malvern 90-Day Model, please give us a call at 610.MALVERN (610.625.8376).

Read the full story on philly.com.

Testimonials

Recent News

Study supports Medication Assisted Treatment for addiction

November 22, 2017 – Addiction experts are always trying to find the most effective methods to treat the disease of addiction. At Malvern Institute, we only use an evidence-based, complete continuum of care, which includes Medication Assisted Treatment (MAT) options. A recent study confirmed the ef...

Read More

See All News

© 2017 Malvern Institute - All Rights Reserved | View Privacy Policy